| NCT ID | NCT02898818 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Turku University Hospital |
| Condition | Healthy |
| Study Type | OBSERVATIONAL |
| Enrollment | 520 participants |
| Start Date | 2017-04-19 |
| Primary Completion | 2026-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 520 participants in total. It began in 2017-04-19 with a primary completion date of 2026-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To study the vaginal and oral microbiome by swab samples. On selected cases, also papa smear will be studied.
Eligibility Criteria
Inclusion Criteria: * patients coming to Turku University Hospital Dermato-Venereology or Gynaecology Departments or to family planning clinics in The wellbeing services county of Southwest Finland for previously mentioned reasons Exclusion Criteria: * those not meeting the criteria
Contact & Investigator
Niina K Hieta, MD, PhD
PRINCIPAL INVESTIGATOR
specialist
Frequently Asked Questions
Who can join the NCT02898818 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Healthy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02898818 currently recruiting?
Yes, NCT02898818 is actively recruiting participants. Contact the research team at niina.hieta@tyks.fi for enrollment information.
Where is the NCT02898818 trial being conducted?
This trial is being conducted at Turku, Finland.
Who is sponsoring the NCT02898818 clinical trial?
NCT02898818 is sponsored by Turku University Hospital. The principal investigator is Niina K Hieta, MD, PhD at specialist. The trial plans to enroll 520 participants.